Biography and Research Information
OverviewAI-generated summary
Jim Jin's research focuses on evaluating the safety and efficacy of novel therapeutic agents for autoimmune diseases. He has published work on the use of monoclonal antibodies, specifically Nipocalimab, in patients with generalized Myasthenia Gravis. His publications include studies detailing the design and outcomes of Phase 2 clinical trials, such as the Vivacity-MG study, which investigated the drug's pharmacokinetics, pharmacodynamics, and immunogenicity. Jin also has research interests extending to respiratory health, as indicated by his involvement in the BREATHE study concerning bronchiolitis recovery. His scholarship metrics include an h-index of 4 and 5 total publications with 100 citations. Jin collaborates with colleagues at the University of Arkansas for Medical Sciences, including Jaime Baldner and Leah Lawrence, with whom he has co-authored publications.
Metrics
- h-index: 16
- Publications: 72
- Citations: 797
Selected Publications
-
The BREATHE Study: A Randomized Controlled Trial of Bronchiolitis Recovery and Use of HEPA Filters (2025)
Collaboration Network
Top Collaborators
Jeffrey T. Guptill
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Carlo Antozzi
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Vera Bril
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Josep Gámez
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Sven G. Meuth
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Richard J. Nowak
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Dianna Quan
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Teresa Sevilla
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Marie‐Hélène Jouvin
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Santiago Arroyo
Heinrich Heine University Düsseldorf (DE)
2 shared publications
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
J.L. Muñoz Blanco
Hospital General Universitario Gregorio Marañón (ES)
1 shared publication
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Andrzej Szczudlik
Jagiellonian University (PL)
1 shared publication
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Brooke Hegarty
Momenta Pharmaceuticals (United States) (US)
1 shared publication
- Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Keith Karcher
Heinrich Heine University Düsseldorf (DE)
1 shared publication
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Sindhu Ramchandren
Heinrich Heine University Düsseldorf (DE)
1 shared publication
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Similar Researchers
Based on overlapping research topics
David S. Henry
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Pooja Modi
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Neurological disorders and treatments
Disease Mechanisms Research
Kenneth Hensley
University of Arkansas – Fort Smith
Immune Response and Inflammation
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Manoja Gullapalli
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Chaow Charoenkijkajorn
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Neurological disorders and treatments
COVID-19 Clinical Research Studies
Narenraj Arulprakash
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies